GlassScriptPhysician profile
Lindsey J Bostelman
NPI 1386888204
$1,271.61
in general payments reported to CMS, 2019-2025
33 companies · $18.72 in 2025
The $18.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $202 · 2021: $319 · 2022: $321 · 2023: $248 · 2024: $33.12 · 2025: $18.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $115.93 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.97 | 2019-2023 | Jardiance |
| Abbvie INC. | $101.61 | 2021-2022 | |
| Amarin Pharma, INC. | $71.90 | 2019-2022 | |
| Exact Sciences Corporation | $67.59 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $65.06 | 2020-2021 | |
| Ucb, INC. | $65.03 | 2021-2023 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $62.72 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.48 | 2021-2023 | Xifaxan |
| Amgen INC. | $47.94 | 2020-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $47.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $42.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.93 | 2022-2023 | |
| Allergan, INC. | $37.73 | 2019-2020 | |
| Glaxosmithkline, LLC. | $30.68 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.24 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $25.76 | 2022-2023 | Austedo |
| Lundbeck LLC | $20.49 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $20.10 | 2021 | |
| Eisai INC. | $19.66 | 2022 | |
| Merck Sharp & Dohme LLC | $19.19 | 2020 | |
| Shield Therapeutics INC | $18.46 | 2023 | Accrufer |
| Genentech USA, INC. | $17.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Sumitomo Pharma America, INC. | $16.36 | 2023 | Gemtesa |
| Lilly USA, LLC | $15.43 | 2022 | |
| Bausch Health US, LLC | $15.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
| Glenmark Therapeutics INC. | $15.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.77 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2020 | |
| Corium, LLC | $11.54 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Bostelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.